Home / Market News / $A

$A news and market catalysts

The 24 most recent market catalysts affecting $A, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

24 catalysts 4 high impact 19 bullish 1 bearish Healthcare Technology
Nov 4, 2026 Corporate Catalyst Bullish Impact 85
Agilent Technologies Completes Acquisition of Proscia
Agilent Technologies announced the completion of its acquisition of Proscia for $240 million in cash, with an additional $30 million contingent on future performance. This acquisit…
Oct 30, 2026 Corporate Catalyst Neutral Impact 55
Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
Agilent Technologies, Inc. (A) has scheduled the release of its Q4 FY26 financial results for November 23, 2026, after market close, followed by a conference call. This is a standa…
Oct 28, 2026 Corporate Catalyst Bearish Impact 55
Evercore ISI Adjusts Price Target on Agilent Technologies
Evercore ISI, a prominent investment bank, has lowered its price target for Agilent Technologies from $178 to $172. This adjustment signals a slightly less favorable view of Agilen…
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
Agilent and University of Chicago Launch Center of Excellence for Energy Materials Research
Agilent Technologies is partnering with the University of Chicago to create a Center of Excellence for Energy Materials Research. This initiative is significant as it positions Agi…
Oct 26, 2026 Corporate Catalyst Neutral Impact 65
Deutsche Bank Initiates Coverage on Agilent Technologies With Buy Rating
Deutsche Bank has initiated coverage on Agilent Technologies, assigning a 'Buy' rating and a $190 price target. This event is significant as new analyst coverage, especially with a…
Oct 14, 2026 Corporate Catalyst Bullish Impact 85
Why Agilent Is Spending up to $270 Million on an AI Pathology Specialist
Agilent Technologies is acquiring Proscia, a digital pathology software provider, for $240 million cash at closing plus $30 million in performance milestones. This acquisition is s…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $196
TD Cowen analyst Dan Brennan has updated their coverage on Agilent Technologies, raising the price target from $180 to $196 while maintaining a 'Buy' rating. This action signals in…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $190
Morgan Stanley analyst Kallum Titchmarsh has maintained an 'Overweight' rating on Agilent Technologies (A) and raised the price target from $175 to $190. This action signals contin…
Oct 13, 2026 Corporate Catalyst Bullish Impact 65
Agilent Announces Deal To Acquire Digital Pathology Software Firm Proscia For $240M Cash, Up To $30M In Milestones
This acquisition is a corporate catalyst for Agilent, signaling its strategic intent to expand into the high-growth digital pathology and AI-driven diagnostics market. The $240M ca…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Agilent Technologies, Raises Price Target to $195
Barclays analyst Luke Sergott has maintained an 'Overweight' rating on Agilent Technologies while simultaneously raising the price target from $175 to $195. This action signals inc…
Sep 4, 2026 Corporate Catalyst Neutral Impact 55
Agilent Technologies Rolls Out Agilent S540MD Slide Scanner System In U.S.
Agilent Technologies has launched its S540MD Slide Scanner System in the U.S. market, a significant step following its FDA clearance. This product introduction expands Agilent's di…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
Stifel Maintains Buy on Agilent Technologies, Raises Price Target to $180
Stifel analyst Daniel Arias has maintained a 'Buy' rating on Agilent Technologies (A) and raised the price target from $170 to $180. This action signals a continued bullish sentime…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Agilent Technologies, Raises Price Target to $190
Citigroup analyst Patrick Donnelly has maintained a 'Buy' rating on Agilent Technologies (A) and raised the price target from $185 to $190. This action signals continued confidence…
Aug 27, 2026 Market Technicals Bullish Impact 55
JP Morgan Maintains Overweight on Agilent Technologies, Raises Price Target to $190
JP Morgan analyst Casey Woodring has maintained an 'Overweight' rating on Agilent Technologies (A) and raised the price target from $180 to $190. This action signals continued conf…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $180
TD Cowen analyst Dan Brennan maintained a 'Buy' rating on Agilent Technologies (A) and raised the price target from $155 to $180. This upward revision in the price target indicates…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
Bernstein Maintains Outperform on Agilent Technologies, Raises Price Target to $180
Bernstein analyst Eve Burstein has maintained an Outperform rating on Agilent Technologies and raised the price target from $155 to $180. This analyst upgrade signals a more optimi…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Agilent Technologies, Raises Price Target to $185
RBC Capital's analyst Dan Leonard has maintained an 'Outperform' rating on Agilent Technologies and raised the price target from $155 to $185. This action signals increased confide…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Group Maintains Outperform on Agilent Technologies, Raises Price Target to $172
Evercore ISI Group, through analyst Vijay Kumar, has maintained its 'Outperform' rating for Agilent Technologies and raised the price target from $148 to $172. This action signals …
Aug 26, 2026 Corporate Catalyst Bullish Impact 92
Agilent Technologies shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY26 guidance above estimates. Also, the company issued Q4 sales guidance above estimates.
This headline represents a major positive corporate catalyst for Agilent Technologies. Better-than-expected Q3 results and, more importantly, raised guidance for both Q4 and FY26, …
Aug 26, 2026 Corporate Catalyst Neutral Impact 75
Agilent Technologies Sees Q4 Adj EPS $1.71-$1.74 vs $1.72 Est; Sees Sales $1.980B-$2.000B vs $1.971B Est
Agilent Technologies released its Q4 guidance, projecting adjusted EPS between $1.71 and $1.74, which is consistent with the analyst consensus of $1.72. More notably, the company's…
Aug 26, 2026 Corporate Catalyst Bullish Impact 92
Agilent Technologies Q3 Adj. EPS $1.62 Beats $1.49 Estimate, Sales $1.878B Beat $1.841B Estimate
Agilent Technologies (A) announced Q3 adjusted EPS of $1.62, significantly exceeding the $1.49 analyst consensus, and sales of $1.878 billion, also beating the $1.841 billion estim…
Aug 12, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $175
Morgan Stanley's analyst Kallum Titchmarsh maintained an 'Overweight' rating on Agilent Technologies and raised the price target from $160 to $175. This action signals continued co…
Jul 23, 2026 Corporate Catalyst Bullish Impact 65
Agilent Technologies shares are trading higher after the company announced it has received EU certification for PD-L1 IHC 22C3 pharmDx, in identifying epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Agilent Technologies announced it has received EU certification for its PD-L1 IHC 22C3 pharmDx, a diagnostic test used to identify epithelial ovarian, fallopian tube, or primary pe…
Jul 23, 2026 Corporate Catalyst Bullish Impact 55
Agilent Technologies Receives EU Certification For Code SK006 As Companion Diagnostic To Aid In Identifying Patients With Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Carcinoma
Agilent Technologies received EU certification for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for specific ovarian, fallopian tube, and primary peritoneal ca…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.